Keywords: aventis, eps, leaps, 2nd, quarter, blockbusters, power
Aventis' EPS leaps 29% in 2nd quarter, blockbusters power growth
Article | 05 August 2002
Franco-German drug major Aventis has reported group net income of 507million euros ($497 million) for second-quarter 2002, an increase of 30%, while earnings ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Elan puts up formal "for sale" notice
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
